Area of research
Oncology · Immunology
Research interest
Dr. Charles G. Drake is a physician-scientist with a Ph.D. in immunology, whose work focuses on understanding and fighting advanced-stage cancers with the immune system. He is known for rapidly incorporating discoveries made in the research lab into innovative clinical trials, including anti-tumor vaccines.
Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer.
Supplementary Fig. S2 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Fig. S7 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Data from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Fig. S4 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Figure 4 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Figure 5 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Figure 3 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Fig. S6 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Figure 2 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Data from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Fig. S3 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Fig. S5 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Fig. S1 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Figure 1 from Human Kallikrein 2: A Novel Lineage-Specific Surface Target in Prostate Cancer
Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
Supplementary Figure 6 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
U.S. Support for the 28th International Geological Congress (IGC)
Travel to Attend: Meeting on Geodynamics Problems - Outlook To the 80's; Zurich, Switzerland; Feb 5-6, 1979
Travel to Visit Peoples Republic of China at the Invitation Of the Geological Society of China, Hong Kong, September 12-October 15, 1977